Mechanisms of modafinil: A review of current research

Modafinil is a widely used wake-promoting agent for sleep disorders, with emerging interest in its potential to treat stimulant addiction and neurodegenerative conditions. Despite its clinical efficacy, its primary mechanism of action (MOA) has remained elusive for nearly a decade. While early research focused on identifying specific receptor binding sites, this review synthesizes evidence suggesting that modafinil's effects are likely more complex than simple monoaminergic stimulation.

Preclinical studies have consistently shown that modafinil influences various neurotransmitter systems, including dopamine, norepinephrine, serotonin, and histamine. However, it does not act as a potent direct agonist or antagonist at these receptors. Instead, research indicates that modafinil may enhance neurotransmitter release through indirect mechanisms, such as modulating GABAergic tone or increasing electrosecretory coupling.

Beyond its wake-promoting properties, modafinil exhibits neuroprotective effects, particularly in models of oxidative stress. The authors highlight that sleep induction and cellular damage share common pathways involving free radicals and adenosine. This suggests that modafinil might act as a common target to oppose both sleep pressure and neurodegeneration, potentially by improving mitochondrial function or scavenging reactive oxygen species.

Human neurocognitive studies demonstrate that modafinil can improve executive function, attention, and impulse control, particularly in sleep-deprived individuals or those with baseline cognitive deficits. Unlike traditional stimulants that cause localized neural excitation, functional imaging studies suggest that modafinil modulates cortical activity in a way that is dependent on baseline activation. This "regulatory" effect supports the hypothesis that modafinil enhances whole-brain efficiency rather than simply increasing raw neural output.